BTIG Lowers PT on Embecta Corp. (EMBC) to $25, Keeps a Buy Rating

Embecta Corp. (NASDAQ:EMBC) is one of the best cheap stocks with huge upside potential. On May 23, BTIG analyst Marie Thibault lowered the firm’s price target on Embecta Corp. (NASDAQ:EMBC) to $25 from $26, keeping a Buy rating on the shares. The rating followed its Investor Day presentation.

The analyst told investors in a research note that Embecta Corp. (NASDAQ:EMBC) reaffirmed its FY2025 guidance, with long-range targets offered through fiscal year 2028.

In addition, Embecta Corp.’s (NASDAQ:EMBC) lower margin outlook compared to fiscal year 2025 reflects pricing pressure, inflationary headwinds, and incremental tariffs. The firm added that these factors are partially offset by cost improvement programs.

Embecta Corp. (NASDAQ:EMBC) provides medical devices used to treat diabetes. The company’s offerings include syringes, pen needles, and safety devices fitted with a digital application.

While we acknowledge the potential of EMBC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.